Aldevron
4055 41st Avenue South
Fargo
North Dakota
58104
United States
24 articles with Aldevron
-
Aldevron the First to Rapidly Discover Human Antibodies Using Ligand's OmniRat® Platform and Berkeley Lights' Beacon® Instrument
8/31/2020
Aldevron the First to Rapidly Discover Human Antibodies Using Ligand's OmniRat ® Platform and Berkeley Lights' Beacon ® Instrument
-
Aldevron Names Cynthia Biffert Vice President of its GMP Nucleic Acids Business Unit
7/14/2020
Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Cynthia Biffert as Vice President of its GMP Nucleic Acids Business Unit (NABU). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005378/en/ Cynthia Biffert, Vice President of Aldevron's GMP Nucleic Acids Business Unit (Photo: Business Wire) Biff
-
Aldevron Announces Agreement with Ziopharm Oncology for neoGMP® Production of Sleeping Beauty Plasmid DNA to Express TCRs for Treatment of Solid Tumors
6/25/2020
Aldevron, a leading provider of products and services for the biotechnology industry, today announced an agreement with Ziopharm Oncology to produce plasmid DNA for T cell therapy of solid tumors.
-
Kevin Ballinger to Assume CEO Role at Aldevron; Michael Chambers to become Executive Chairman
6/24/2020
Attracting one of med-tech’s most accomplished executives, Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13, 2020.
-
Aldevron Appoints James Brown, Ph.D. President of Research Grade Nucleic Acids Business Unit
5/12/2020
Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Dr. James Brown President of its Research Grade nucleic acids business unit.
-
Aldevron Announces Second Breakthrough Symposium
2/18/2020
Feb. 18, 2020 14:30 UTC FARGO, N.D.--( BUSINESS WIRE )-- Aldevron, a global leader in the custom development and manufacture of plasmid DNA, protein, mRNA and antibodies for the biotech industry, is hosting its second Breakthrough Symposium with the theme “Pioneering Biotech,” September 28-30, 2020, in Fargo, N.D., home to Aldevron’s headquarters and main campus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218
-
Phase one of the construction project will start in August. Once completed, its annual capacity will be more than $1 billion of plasmid DNA, RNA, gene editing enzymes and other biologics.
-
Aldevron Announces Expansion of Antibody Development Facility
3/4/2019
Increasing GENOVAC platform capacity and antibody development services necessary to meet demand
-
Aldevron Announces Ready-to-Use AAV Helper Plasmid
2/21/2018
New plasmid to reduce cost and timeline for gene therapy manufacturing.
-
Aldevron to Provide New GMP Cas9 Nuclease Through Agreement With Integrated DNA Technologies
12/12/2017
Aldevron and DNA Technologies. Inc. announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFi Cas9 Nuclease—which is patented by IDT.
-
Aldevron Names Dr. Thomas Lynch Vice President Of Sales And Client Development
8/22/2017
-
Aldevron Names Biomanufacturing Veteran Henry Hebel As New Chief Operating Officer
5/24/2017
-
Aldevron Licenses Minicircle Technology To Support Collaboration With Myeloma Crowd And The Development Of Multiple Myeloma Treatments
3/29/2017
-
Aldevron Release: Company Announces Growth Investment From TA Associates
1/24/2017
-
Aldevron Manufactures Malaria DNA Vaccine For Naval Medical Research Center
8/16/2016
-
Aldevron Communicates Commitment To Clients’ Therapeutic Breakthroughs And Discoveries
6/16/2016
-
Aldevron's Facility Expansion to Create 30 New Jobs By End of 2016
3/30/2016
-
Aldevron, LLC Appoints Jenny Stafford As Vice President And General Manager
2/17/2016
-
Aldevron, LLC Appoints Dr. James Brown As Vice President Of Corporate Development
1/28/2016
-
Madison Biotech Supplier, Aldevron, LLC, Goes Lean To Stave Off Foreign Competitors
2/19/2014